Skip to main content
Erschienen in: Inflammation 6/2023

21.08.2023 | RESEARCH

The Anti-Inflammatory Effect of a Probiotic Cocktail in Human Feces Induced-Mouse Model

verfasst von: Afsaneh Salimi, Amin Sepehr, Niloofar Hejazifar, Maliheh Talebi, Mahdi Rohani, Mohammad Reza Pourshafie

Erschienen in: Inflammation | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract due to altered interaction between the immune system and the gut microbiota. The aim of this study was to investigate the role of a probiotic cocktail in modulating immune dysregulation induced in mice. Mice were divided into 5 groups (n = 5/group), and inflammation was induced in two separate groups by fecal microbiota transplantation (FMT) from the stool of human with IBD and dextran sulfate sodium (DSS). In the other two groups, the cocktail of Lactobacillus spp. and Bifidobacterium spp. (108CFU/kg/day) was administered daily for a total of 28days in addition to inducing inflammation. A group as a contcxsrol group received only water and food. The alteration of the selected genera of gut microbiota and the expression of some genes involved in the regulation of the inflammatory response were studied in the probiotic-treated and untreated groups by quantitative real-time PCR. The selected genera of gut microbiota of the FMT and DSS groups showed similar patterns on day 28 after each treatment. In the probiotic-treated groups, the population of the selected genera of gut microbiota normalized and the abundance of Firmicutes and Actinobacteria increased compared to the DSS and FMT groups. The expression of genes related to immune response and tight junctions was positively affected by the probiotic. Changes in the gut microbiota could influence the inflammatory status in the gut, and probiotics as a preventive or complementary treatment could improve the well-being of patients with inflammatory bowel disease symptoms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Negi, S., S. Saini, N. Tandel, K. Sahu, R.P. Mishra, and R.K. Tyagi. 2021. Translating Treg therapy for inflammatory bowel disease in humanized mice. Cells 10: 1847.PubMedPubMedCentralCrossRef Negi, S., S. Saini, N. Tandel, K. Sahu, R.P. Mishra, and R.K. Tyagi. 2021. Translating Treg therapy for inflammatory bowel disease in humanized mice. Cells 10: 1847.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Baumgart, D.C., and S.R. Carding. 2007. Inflammatory bowel disease: Cause and immunobiology. The Lancet 369: 1627–1640.CrossRef Baumgart, D.C., and S.R. Carding. 2007. Inflammatory bowel disease: Cause and immunobiology. The Lancet 369: 1627–1640.CrossRef
3.
Zurück zum Zitat Sun, Y., L. Li, Y. Xia, W. Li, K. Wang, L. Wang, et al. 2019. The gut microbiota heterogeneity and assembly changes associated with the IBD. Scientific reports 9: 1–8. Sun, Y., L. Li, Y. Xia, W. Li, K. Wang, L. Wang, et al. 2019. The gut microbiota heterogeneity and assembly changes associated with the IBD. Scientific reports 9: 1–8.
4.
Zurück zum Zitat Kaser, A., E. Martínez-Naves, and R.S. Blumberg. 2010. Endoplasmic reticulum stress: Implications for inflammatory bowel disease pathogenesis. Current opinion in gastroenterology 26: 318.PubMedPubMedCentralCrossRef Kaser, A., E. Martínez-Naves, and R.S. Blumberg. 2010. Endoplasmic reticulum stress: Implications for inflammatory bowel disease pathogenesis. Current opinion in gastroenterology 26: 318.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Eckmann, L. 2012. Ingrid Ordás, Lars Eckmann, Mark Talamini, Daniel C Baumgart. William J Sandborn. Lancet 380: 1606–1619.PubMed Eckmann, L. 2012. Ingrid Ordás, Lars Eckmann, Mark Talamini, Daniel C Baumgart. William J Sandborn. Lancet 380: 1606–1619.PubMed
6.
Zurück zum Zitat Bjerrum, J.T., Y. Wang, F. Hao, M. Coskun, C. Ludwig, U. Günther, et al. 2015. Metabonomics of human fecal extracts characterize ulcerative colitis. Crohn’s disease and healthy individuals. Metabolomics 11: 122–133.PubMed Bjerrum, J.T., Y. Wang, F. Hao, M. Coskun, C. Ludwig, U. Günther, et al. 2015. Metabonomics of human fecal extracts characterize ulcerative colitis. Crohn’s disease and healthy individuals. Metabolomics 11: 122–133.PubMed
7.
Zurück zum Zitat Ananthakrishnan, A.N. 2015. Epidemiology and risk factors for IBD. Nature reviews Gastroenterology & hepatology 12: 205–217.CrossRef Ananthakrishnan, A.N. 2015. Epidemiology and risk factors for IBD. Nature reviews Gastroenterology & hepatology 12: 205–217.CrossRef
8.
Zurück zum Zitat Shin, J.-H., Y.-K. Lee, W.-J. Shon, B. Kim, C.O. Jeon, J.-Y. Cho, et al. 2020. Gut microorganisms and their metabolites modulate the severity of acute colitis in a tryptophan metabolism-dependent manner. European Journal of Nutrition 59: 3591–3601.PubMedCrossRef Shin, J.-H., Y.-K. Lee, W.-J. Shon, B. Kim, C.O. Jeon, J.-Y. Cho, et al. 2020. Gut microorganisms and their metabolites modulate the severity of acute colitis in a tryptophan metabolism-dependent manner. European Journal of Nutrition 59: 3591–3601.PubMedCrossRef
9.
Zurück zum Zitat Qin, J., R. Li, J. Raes, M. Arumugam, K.S. Burgdorf, C. Manichanh, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59–65.PubMedPubMedCentralCrossRef Qin, J., R. Li, J. Raes, M. Arumugam, K.S. Burgdorf, C. Manichanh, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59–65.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Wrzosek, L., D. Ciocan, P. Borentain, M. Spatz, V. Puchois, C. Hugot, et al. 2018. Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota. Scientific reports 8: 1–9.CrossRef Wrzosek, L., D. Ciocan, P. Borentain, M. Spatz, V. Puchois, C. Hugot, et al. 2018. Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota. Scientific reports 8: 1–9.CrossRef
11.
Zurück zum Zitat Wang, W., L. Chen, R. Zhou, X. Wang, L. Song, S. Huang, et al. 2014. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. Journal of clinical microbiology 52: 398–406.PubMedPubMedCentralCrossRef Wang, W., L. Chen, R. Zhou, X. Wang, L. Song, S. Huang, et al. 2014. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. Journal of clinical microbiology 52: 398–406.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Machiels, K., M. Joossens, J. Sabino, V. De Preter, I. Arijs, V. Eeckhaut, et al. 2014. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63: 1275–1283.PubMedCrossRef Machiels, K., M. Joossens, J. Sabino, V. De Preter, I. Arijs, V. Eeckhaut, et al. 2014. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63: 1275–1283.PubMedCrossRef
13.
Zurück zum Zitat Rehman, A., P. Rausch, J. Wang, J. Skieceviciene, G. Kiudelis, K. Bhagalia, et al. 2016. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut 65: 238–248.PubMedCrossRef Rehman, A., P. Rausch, J. Wang, J. Skieceviciene, G. Kiudelis, K. Bhagalia, et al. 2016. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut 65: 238–248.PubMedCrossRef
14.
Zurück zum Zitat Prosberg, M., F. Bendtsen, I. Vind, A.M. Petersen, and L.L. Gluud. 2016. The association between the gut microbiota and the inflammatory bowel disease activity: A systematic review and meta-analysis. Scandinavian journal of gastroenterology 51: 1407–1415.PubMedCrossRef Prosberg, M., F. Bendtsen, I. Vind, A.M. Petersen, and L.L. Gluud. 2016. The association between the gut microbiota and the inflammatory bowel disease activity: A systematic review and meta-analysis. Scandinavian journal of gastroenterology 51: 1407–1415.PubMedCrossRef
15.
Zurück zum Zitat Rosen, C.E., and N.W. Palm. 2018. Navigating the microbiota seas: Triangulation finds a way forward. Cell Host & Microbe 23: 1–3.CrossRef Rosen, C.E., and N.W. Palm. 2018. Navigating the microbiota seas: Triangulation finds a way forward. Cell Host & Microbe 23: 1–3.CrossRef
16.
Zurück zum Zitat Gkouskou, K.K., C. Deligianni, C. Tsatsanis, and A.G. Eliopoulos. 2014. The gut microbiota in mouse models of inflammatory bowel disease. Frontiers in cellular and infection microbiology 4: 28.PubMedPubMedCentralCrossRef Gkouskou, K.K., C. Deligianni, C. Tsatsanis, and A.G. Eliopoulos. 2014. The gut microbiota in mouse models of inflammatory bowel disease. Frontiers in cellular and infection microbiology 4: 28.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Nanda, K., and A.C. Moss. 2012. Update on the management of ulcerative colitis: Treatment and maintenance approaches focused on MMX® mesalamine. Clinical pharmacology: Advances and applications 4: 41.PubMed Nanda, K., and A.C. Moss. 2012. Update on the management of ulcerative colitis: Treatment and maintenance approaches focused on MMX® mesalamine. Clinical pharmacology: Advances and applications 4: 41.PubMed
18.
Zurück zum Zitat Rhen, T., and J.A. Cidlowski. 2005. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. New England Journal of Medicine 353: 1711–1723.PubMedCrossRef Rhen, T., and J.A. Cidlowski. 2005. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. New England Journal of Medicine 353: 1711–1723.PubMedCrossRef
19.
Zurück zum Zitat Habens, F., N. Srinivasan, F. Oakley, D. Mann, A. Ganesan, and G. Packham. 2005. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 10: 481–491.PubMedCrossRef Habens, F., N. Srinivasan, F. Oakley, D. Mann, A. Ganesan, and G. Packham. 2005. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 10: 481–491.PubMedCrossRef
20.
Zurück zum Zitat Nugent, S., D. Kumar, D. Rampton, and D. Evans. 2001. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48: 571–577.PubMedPubMedCentralCrossRef Nugent, S., D. Kumar, D. Rampton, and D. Evans. 2001. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48: 571–577.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat van Dieren, J.M., E.J. Kuipers, J.N. Samsom, E.E. Nieuwenhuis, and J.C. van der Woude. 2006. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD. Inflammatory bowel diseases 12: 311–327.PubMedCrossRef van Dieren, J.M., E.J. Kuipers, J.N. Samsom, E.E. Nieuwenhuis, and J.C. van der Woude. 2006. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD. Inflammatory bowel diseases 12: 311–327.PubMedCrossRef
22.
Zurück zum Zitat Willot, S., A. Noble, and C. Deslandres. 2011. Methotrexate in the treatment of inflammatory bowel disease: An 8-year retrospective study in a Canadian pediatric IBD center. Inflammatory bowel diseases 17: 2521–2526.PubMedCrossRef Willot, S., A. Noble, and C. Deslandres. 2011. Methotrexate in the treatment of inflammatory bowel disease: An 8-year retrospective study in a Canadian pediatric IBD center. Inflammatory bowel diseases 17: 2521–2526.PubMedCrossRef
23.
Zurück zum Zitat Triantafillidis, J.K., E. Merikas, and F. Georgopoulos. 2011. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug design, development and therapy 5: 185.PubMedPubMedCentralCrossRef Triantafillidis, J.K., E. Merikas, and F. Georgopoulos. 2011. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug design, development and therapy 5: 185.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Khan, I., N. Ullah, L. Zha, Y. Bai, A. Khan, T. Zhao, et al. 2019. Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome. Pathogens 8: 126.PubMedPubMedCentralCrossRef Khan, I., N. Ullah, L. Zha, Y. Bai, A. Khan, T. Zhao, et al. 2019. Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome. Pathogens 8: 126.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Bengmark, S. 2001. Pre-, pro-and synbiotics. Current Opinion in Clinical Nutrition & Metabolic Care 4: 571–579.CrossRef Bengmark, S. 2001. Pre-, pro-and synbiotics. Current Opinion in Clinical Nutrition & Metabolic Care 4: 571–579.CrossRef
26.
Zurück zum Zitat Rioux, K.P., and R.N. Fedorak. 2006. Probiotics in the treatment of inflammatory bowel disease. Journal of clinical gastroenterology 40: 260–263.PubMedCrossRef Rioux, K.P., and R.N. Fedorak. 2006. Probiotics in the treatment of inflammatory bowel disease. Journal of clinical gastroenterology 40: 260–263.PubMedCrossRef
27.
Zurück zum Zitat Madsen, K.L., J.S. Doyle, L.D. Jewell, M.M. Tavernini, and R.N. Fedorak. 1999. Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice. Gastroenterology 116: 1107–1114.PubMedCrossRef Madsen, K.L., J.S. Doyle, L.D. Jewell, M.M. Tavernini, and R.N. Fedorak. 1999. Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice. Gastroenterology 116: 1107–1114.PubMedCrossRef
28.
Zurück zum Zitat Zhou, L., D. Liu, Y. Xie, X. Yao, and Y. Li. 2019. Bifidobacterium infantis induces protective colonic PD-L1 and Foxp3 regulatory T cells in an acute murine experimental model of inflammatory bowel disease. Gut and Liver 13: 430.PubMedPubMedCentralCrossRef Zhou, L., D. Liu, Y. Xie, X. Yao, and Y. Li. 2019. Bifidobacterium infantis induces protective colonic PD-L1 and Foxp3 regulatory T cells in an acute murine experimental model of inflammatory bowel disease. Gut and Liver 13: 430.PubMedPubMedCentralCrossRef
29.
30.
Zurück zum Zitat Salimi, A., A. Sepehr, H. Ajdarkosh, S. Aghamohamad, M. Talebi, and M.R. Pourshafie. 2022. Dynamic population of gut microbiota as an indicator of inflammatory bowel disease. Iranian biomedical journal 26: 350–356.PubMedPubMedCentralCrossRef Salimi, A., A. Sepehr, H. Ajdarkosh, S. Aghamohamad, M. Talebi, and M.R. Pourshafie. 2022. Dynamic population of gut microbiota as an indicator of inflammatory bowel disease. Iranian biomedical journal 26: 350–356.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Bartosch, S., A. Fite, G.T. Macfarlane, and M.E. McMurdo. 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Applied and environmental microbiology 70: 3575–3581.PubMedPubMedCentralCrossRef Bartosch, S., A. Fite, G.T. Macfarlane, and M.E. McMurdo. 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Applied and environmental microbiology 70: 3575–3581.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat De Gregoris, T.B., N. Aldred, A.S. Clare, and J.G. Burgess. 2011. Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa. Journal of microbiological methods 86: 351–356.CrossRef De Gregoris, T.B., N. Aldred, A.S. Clare, and J.G. Burgess. 2011. Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa. Journal of microbiological methods 86: 351–356.CrossRef
33.
Zurück zum Zitat Haarman, M., and J. Knol. 2006. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Applied and environmental microbiology 72: 2359–2365.PubMedPubMedCentralCrossRef Haarman, M., and J. Knol. 2006. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Applied and environmental microbiology 72: 2359–2365.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Larsen, N., F.K. Vogensen, F.W. Van Den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen, et al. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5: e9085.PubMedPubMedCentralCrossRef Larsen, N., F.K. Vogensen, F.W. Van Den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen, et al. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5: e9085.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Jia, W., R.N. Whitehead, L. Griffiths, C. Dawson, R.H. Waring, D.B. Ramsden, et al. 2010. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS microbiology letters 310: 138–144.PubMedCrossRef Jia, W., R.N. Whitehead, L. Griffiths, C. Dawson, R.H. Waring, D.B. Ramsden, et al. 2010. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS microbiology letters 310: 138–144.PubMedCrossRef
36.
Zurück zum Zitat Eshaghi, M., M.H. Bibalan, M. Rohani, M. Esghaei, M. Douraghi, M. Talebi, et al. 2017. Bifidobacterium obtained from mother’s milk and their infant stool; A comparative genotyping and antibacterial analysis. Microbial pathogenesis 111: 94–98.PubMedCrossRef Eshaghi, M., M.H. Bibalan, M. Rohani, M. Esghaei, M. Douraghi, M. Talebi, et al. 2017. Bifidobacterium obtained from mother’s milk and their infant stool; A comparative genotyping and antibacterial analysis. Microbial pathogenesis 111: 94–98.PubMedCrossRef
37.
Zurück zum Zitat Rohani, M., N. Noohi, M. Talebi, M. Katouli, and M.R. Pourshafie. 2015. Highly heterogeneous probiotic Lactobacillus species in healthy Iranians with low functional activities. PLoS ONE 10: e0144467.PubMedPubMedCentralCrossRef Rohani, M., N. Noohi, M. Talebi, M. Katouli, and M.R. Pourshafie. 2015. Highly heterogeneous probiotic Lactobacillus species in healthy Iranians with low functional activities. PLoS ONE 10: e0144467.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Aghamohammad, S., A. Sepehr, S.T. Miri, S. Najafi, M.R. Pourshafie, and M. Rohani. 2022. The role of combining probiotics in preventing and controlling inflammation: a focus on the anti-inflammatory and immunomodulatory effects of probiotics in an in vitro model of IBD. Canadian Journal of Gastroenterology and Hepatology 2022. Aghamohammad, S., A. Sepehr, S.T. Miri, S. Najafi, M.R. Pourshafie, and M. Rohani. 2022. The role of combining probiotics in preventing and controlling inflammation: a focus on the anti-inflammatory and immunomodulatory effects of probiotics in an in vitro model of IBD. Canadian Journal of Gastroenterology and Hepatology 2022.
39.
Zurück zum Zitat Miri, S.T., F. Sotoodehnejadnematalahi, M.M. Amiri, M.R. Pourshafie, and M. Rohani. 2022. The impact of Lactobacillus and Bifidobacterium probiotic cocktail on modulation of gene expression of gap junctions dysregulated by intestinal pathogens. Archives of Microbiology 204: 417.PubMedCrossRef Miri, S.T., F. Sotoodehnejadnematalahi, M.M. Amiri, M.R. Pourshafie, and M. Rohani. 2022. The impact of Lactobacillus and Bifidobacterium probiotic cocktail on modulation of gene expression of gap junctions dysregulated by intestinal pathogens. Archives of Microbiology 204: 417.PubMedCrossRef
40.
Zurück zum Zitat Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25: 402–408.PubMedCrossRef Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25: 402–408.PubMedCrossRef
41.
Zurück zum Zitat Wei, Y.-L., Y.-Q. Chen, H. Gong, N. Li, K.-Q. Wu, W. Hu, et al. 2018. Fecal microbiota transplantation ameliorates experimentally induced colitis in mice by upregulating AhR. Frontiers in microbiology 9: 1921.PubMedPubMedCentralCrossRef Wei, Y.-L., Y.-Q. Chen, H. Gong, N. Li, K.-Q. Wu, W. Hu, et al. 2018. Fecal microbiota transplantation ameliorates experimentally induced colitis in mice by upregulating AhR. Frontiers in microbiology 9: 1921.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Arrieta, M.-C., J. Walter, and B.B. Finlay. 2016. Human microbiota-associated mice: A model with challenges. Cell host & microbe 19: 575–578.CrossRef Arrieta, M.-C., J. Walter, and B.B. Finlay. 2016. Human microbiota-associated mice: A model with challenges. Cell host & microbe 19: 575–578.CrossRef
43.
Zurück zum Zitat Tomas, J., L. Wrzosek, N. Bouznad, S. Bouet, C. Mayeur, M.L. Noordine, et al. 2013. Primocolonization is associated with colonic epithelial maturation during conventionalization. The FASEB Journal 27: 645–655.PubMedCrossRef Tomas, J., L. Wrzosek, N. Bouznad, S. Bouet, C. Mayeur, M.L. Noordine, et al. 2013. Primocolonization is associated with colonic epithelial maturation during conventionalization. The FASEB Journal 27: 645–655.PubMedCrossRef
44.
Zurück zum Zitat Chung, H., S.J. Pamp, J.A. Hill, N.K. Surana, S.M. Edelman, E.B. Troy, et al. 2012. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149: 1578–1593.PubMedPubMedCentralCrossRef Chung, H., S.J. Pamp, J.A. Hill, N.K. Surana, S.M. Edelman, E.B. Troy, et al. 2012. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149: 1578–1593.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Gaboriau-Routhiau, V., S. Rakotobe, E. Lécuyer, I. Mulder, A. Lan, C. Bridonneau, et al. 2009. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31: 677–689.PubMedCrossRef Gaboriau-Routhiau, V., S. Rakotobe, E. Lécuyer, I. Mulder, A. Lan, C. Bridonneau, et al. 2009. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31: 677–689.PubMedCrossRef
46.
Zurück zum Zitat Vich Vila, A., F. Imhann, V. Collij, S.A. Jankipersadsing, T. Gurry, Z. Mujagic, et al. 2018. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Science Translational Medicine 10: eaap8914.PubMedCrossRef Vich Vila, A., F. Imhann, V. Collij, S.A. Jankipersadsing, T. Gurry, Z. Mujagic, et al. 2018. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Science Translational Medicine 10: eaap8914.PubMedCrossRef
47.
Zurück zum Zitat Chou, Y.-C., P.-Y. Ho, W.-J. Chen, S.-H. Wu, and M.-H. Pan. 2020. Lactobacillus fermentum V3 ameliorates colitis-associated tumorigenesis by modulating the gut microbiome. American journal of cancer research 10: 1170.PubMedPubMedCentral Chou, Y.-C., P.-Y. Ho, W.-J. Chen, S.-H. Wu, and M.-H. Pan. 2020. Lactobacillus fermentum V3 ameliorates colitis-associated tumorigenesis by modulating the gut microbiome. American journal of cancer research 10: 1170.PubMedPubMedCentral
48.
Zurück zum Zitat Wei, J., and J. Feng. 2010. Signaling pathways associated with inflammatory bowel disease. Recent patents on inflammation & allergy drug discovery 4: 105–117.CrossRef Wei, J., and J. Feng. 2010. Signaling pathways associated with inflammatory bowel disease. Recent patents on inflammation & allergy drug discovery 4: 105–117.CrossRef
49.
Zurück zum Zitat Didierlaurent, A., J.C. Sirard, J.P. Kraehenbuhl, and M.R. Neutra. 2002. How the gut senses its content. Cellular microbiology 4: 61–72.PubMedCrossRef Didierlaurent, A., J.C. Sirard, J.P. Kraehenbuhl, and M.R. Neutra. 2002. How the gut senses its content. Cellular microbiology 4: 61–72.PubMedCrossRef
50.
Zurück zum Zitat Sansonetti, P.J. 2004. War and peace at mucosal surfaces. Nature Reviews Immunology 4: 953–964.PubMedCrossRef Sansonetti, P.J. 2004. War and peace at mucosal surfaces. Nature Reviews Immunology 4: 953–964.PubMedCrossRef
51.
Zurück zum Zitat Burgueño, J.F., and M.T. Abreu. 2020. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nature Reviews Gastroenterology & Hepatology 17: 263–278.CrossRef Burgueño, J.F., and M.T. Abreu. 2020. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nature Reviews Gastroenterology & Hepatology 17: 263–278.CrossRef
52.
Zurück zum Zitat Takeda, K., and S. Akira. 2004. TLR signaling pathways. In Seminars in immunology, vol. 16. Elsevier. Takeda, K., and S. Akira. 2004. TLR signaling pathways. In Seminars in immunology, vol. 16. Elsevier.
53.
Zurück zum Zitat Maldonado Galdeano M.C., J.M. Lemme Dumit, N. Thieblemont, E. Carmuega, R. Weill, G.dV. Perdigon. 2015. Stimulation of innate immune cells induced by probiotics: participation of toll-like receptors. Maldonado Galdeano M.C., J.M. Lemme Dumit, N. Thieblemont, E. Carmuega, R. Weill, G.dV. Perdigon. 2015. Stimulation of innate immune cells induced by probiotics: participation of toll-like receptors.
54.
Zurück zum Zitat Lee, S.I., H.S. Kim, J.M. Koo, and I.H. Kim. 2016. Lactobacillus acidophilus modulates inflammatory activity by regulating the TLR4 and NF-κB expression in porcine peripheral blood mononuclear cells after lipopolysaccharide challenge. British Journal of Nutrition 115: 567–575.PubMedCrossRef Lee, S.I., H.S. Kim, J.M. Koo, and I.H. Kim. 2016. Lactobacillus acidophilus modulates inflammatory activity by regulating the TLR4 and NF-κB expression in porcine peripheral blood mononuclear cells after lipopolysaccharide challenge. British Journal of Nutrition 115: 567–575.PubMedCrossRef
55.
Zurück zum Zitat von Schillde, M.-A., G. Hörmannsperger, M. Weiher, C.-A. Alpert, H. Hahne, C. Bäuerl, et al. 2012. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell host & microbe 11: 387–396.CrossRef von Schillde, M.-A., G. Hörmannsperger, M. Weiher, C.-A. Alpert, H. Hahne, C. Bäuerl, et al. 2012. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell host & microbe 11: 387–396.CrossRef
56.
Zurück zum Zitat Yao, P., F. Tan, H. Gao, L. Wang, T. Yang, and Y. Cheng. 2017. Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2, 4, 6-trinitro-benzene sulfonic acid. Molecular Medicine Reports 15: 1973–1980.PubMedPubMedCentralCrossRef Yao, P., F. Tan, H. Gao, L. Wang, T. Yang, and Y. Cheng. 2017. Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2, 4, 6-trinitro-benzene sulfonic acid. Molecular Medicine Reports 15: 1973–1980.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Petit, C.S., F. Barreau, L. Besnier, P. Gandille, B. Riveau, D. Chateau, et al. 2012. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology 143 (122–132): e15. Petit, C.S., F. Barreau, L. Besnier, P. Gandille, B. Riveau, D. Chateau, et al. 2012. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology 143 (122–132): e15.
58.
Zurück zum Zitat Xu, C.-M., X.-M. Li, B.-Z. Qin, and B. Liu. 2016. Effect of tight junction protein of intestinal epithelium and permeability of colonic mucosa in pathogenesis of injured colonic barrier during chronic recovery stage of rats with inflammatory bowel disease. Asian Pacific Journal of Tropical Medicine 9: 148–152.PubMedCrossRef Xu, C.-M., X.-M. Li, B.-Z. Qin, and B. Liu. 2016. Effect of tight junction protein of intestinal epithelium and permeability of colonic mucosa in pathogenesis of injured colonic barrier during chronic recovery stage of rats with inflammatory bowel disease. Asian Pacific Journal of Tropical Medicine 9: 148–152.PubMedCrossRef
59.
Zurück zum Zitat Zeissig, S., N. Bürgel, D. Günzel, J. Richter, J. Mankertz, U. Wahnschaffe, et al. 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 56: 61–72.PubMedCrossRef Zeissig, S., N. Bürgel, D. Günzel, J. Richter, J. Mankertz, U. Wahnschaffe, et al. 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 56: 61–72.PubMedCrossRef
60.
Zurück zum Zitat Anderson, R.C., A.L. Cookson, W.C. McNabb, Z. Park, M.J. McCann, W.J. Kelly, et al. 2010. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC microbiology 10: 1–11.CrossRef Anderson, R.C., A.L. Cookson, W.C. McNabb, Z. Park, M.J. McCann, W.J. Kelly, et al. 2010. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC microbiology 10: 1–11.CrossRef
61.
Zurück zum Zitat Zhang, Y., X. Zhao, Y. Zhu, J. Ma, H. Ma, and H. Zhang. 2018. Probiotic mixture protects dextran sulfate sodium-induced colitis by altering tight junction protein expressions and increasing Tregs. Mediators of Inflammation 2018. Zhang, Y., X. Zhao, Y. Zhu, J. Ma, H. Ma, and H. Zhang. 2018. Probiotic mixture protects dextran sulfate sodium-induced colitis by altering tight junction protein expressions and increasing Tregs. Mediators of Inflammation 2018.
Metadaten
Titel
The Anti-Inflammatory Effect of a Probiotic Cocktail in Human Feces Induced-Mouse Model
verfasst von
Afsaneh Salimi
Amin Sepehr
Niloofar Hejazifar
Maliheh Talebi
Mahdi Rohani
Mohammad Reza Pourshafie
Publikationsdatum
21.08.2023
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01870-x

Weitere Artikel der Ausgabe 6/2023

Inflammation 6/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.